Marker Therapeutics, Inc. financial data

Symbol
MRKR on Nasdaq
Location
Houston, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 556% % 12%
Debt-to-equity 22% % -13%
Return On Equity -92% % -2.4%
Return On Assets -76% % -5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16,673,127 shares 87%
Common Stock, Shares, Outstanding 16,700,000 shares 88%
Entity Public Float $48,450,000 USD 110%
Common Stock, Value, Issued $16,672 USD 87%
Weighted Average Number of Shares Outstanding, Basic 16,757,678 shares 88%
Weighted Average Number of Shares Outstanding, Diluted 16,757,678 shares 88%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $14,744,508 USD 34%
General and Administrative Expense $4,365,195 USD -4.9%
Operating Income (Loss) $14,867,849 USD -46%
Net Income (Loss) Attributable to Parent $14,298,034 USD -47%
Earnings Per Share, Basic -1 USD/shares -11%
Earnings Per Share, Diluted -1 USD/shares -11%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $17,589,978 USD 95%
Assets, Current $21,734,830 USD 99%
Assets $21,734,830 USD 99%
Accounts Payable, Current $951,000 USD -50%
Employee-related Liabilities, Current $49,000 USD 26%
Liabilities, Current $3,345,937 USD -3.3%
Liabilities $3,345,937 USD -3.3%
Retained Earnings (Accumulated Deficit) $457,477,588 USD -3.2%
Stockholders' Equity Attributable to Parent $18,388,893 USD 147%
Liabilities and Equity $21,734,830 USD 99%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,499,737 USD -43%
Net Cash Provided by (Used in) Financing Activities $49,096 USD -92%
Common Stock, Shares Authorized 30,000,000 shares 0%
Common Stock, Shares, Issued 16,700,000 shares 88%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $18,942,953 USD 110%
Deferred Tax Assets, Valuation Allowance $40,997,000 USD 3.2%
Deferred Tax Assets, Gross $40,997,000 USD 3.2%
Deferred Tax Assets, Operating Loss Carryforwards $30,725,000 USD 4.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $475,849,809 USD 5.6%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $477,000 USD 42%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%